Search Results for: About
Ex-NattoPharma-sponsored survey revealed consumers are actively pursuing healthier arteries through supplementation. Heart Health ranks as one of the top 3 reasons respondents use dietary supplements. At the request of ex-NattoPharma USA, Inc., Discover Research Group surveyed a total of 380 health- and nutrition-minded individuals regarding heart health in October 2015. The survey focused on answering … Continue reading Consumer Survey Shows Interest in Supplements for Artery Health
Ex-NattoPharma-sponsored survey revealed consumers are actively pursuing healthier arteries through supplementation.
Heart Health ranks as one of the top 3 reasons respondents use dietary supplements.
At the request of ex-NattoPharma USA, Inc., Discover Research Group surveyed a total of 380 health- and nutrition-minded individuals regarding heart health in October 2015. The survey focused on answering three primary questions:
1. How concerned are people with the health of their heart?
2. Do they believe that hard arteries are a problem that is associated with poor heart health?
3. How willing would they be to take a supplement to improve the health of their heart by preventing (and even reversing) the hardening of their arteries?
Key Findings: Of the 380 individuals surveyed:
• 87% currently take vitamins or supplements to improve their health.
• 25% identify themselves as having a condition associated with heart disease; 40% have someone in their immediate family with a condition associated with heart disease.
• 35% are very concerned that hardening of the arteries will have a negative impact on their heart health.
• 67% of those surveyed (n = 380) would take a supplement shown to stop hardening of the arteries if the supplement carried no side effects and is priced about the same as other heart health supplements.
Bone and Heart Health are the top reasons customers supplement (reason 2 and 3, respectively). When asked how concerned they were about their heart health on a scale of 1-7, 62% rated their level of concern as 5 or greater (38% rated their level of concern 6 or greater).
Of those who indicated that they or their family member currently has a heart condition (n=232),
• 84% are currently taking a prescription medicine (55% would consider taking a prescription)
• 44% are currently taking a supplement (59% would consider taking a supplement)
Of those who indicated that they currently do not have a heart condition (n=148), for those surveyed between 30 and 40 years old, supplements would be their No. 1 action if they developed heart disease.
“Just over one-third of survey participants ranked ‘hardening of the arteries’ as one of the top 3 risk factors associated with heart disease. This is a concern with growing awareness with Americans, but a natural solution to address this concern was not previously available,” said Eric Anderson, senior vice president of global sales and marketing with ex-NattoPharma, exclusive global supplier of MenaQ7® Vitamin K2 as MK-7. “However, our clinical trials have shown that MenaQ7 addresses 2 of the top 3 reasons that health-minded consumers supplement: MenaQ7 not only protects against age-related hardening of the arteries and regressed arterial stiffening, but it also has been shown to improve bone mineral density and strength.”
MenaQ7® Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos. Ex-NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”. Biolab … Continue reading Product Launch in Brazil
MenaQ7® Vitamin K2 selected by Biolab Farmacêutica, one of Brazil’s largest pharmaceutical cos.
Ex-NattoPharma welcomed the opportunity to support the launch of a new product featuring MenaQ7® Vitamin K2 as MK-7, Doiska MenaQ7, for an audience of more than 600 cardiologists in São Paulo, Brazil. “Dois” is “Two” in Portugese, and “ka” signifies “K”.
Biolab Farmacêutica is one of the largest pharmaceutical companies in Brazil, and the No. 1 pharmaceutical company for cardiology prescriptions. More than 600 cardiologists attended the event hosted by Biolab, and NattoPharma, world leaders in Vitamin K2 research and development, had representatives on hand to explain the substantial body of science supporting MenaQ7 Vitamin K2 as MK-7, specifically the cardiovascular benefits.
“It was our pleasure to participate in the Brazilian launch of Doiska MenaQ7, and a privilege to present our clinical substantiation to more than 600 engaged cardiologists in São Paulo,” says Dr. Hogne Vik, ex-NattoPharma Chief Medical Officer, who presented alongside respected cardiologist Prof. Dr. Francisco Fonseca.
According to Flavio Zemella, Biolab Marketing Director, the symposium was very successful and physicians are excited about Doiska MenaQ7® arrival in the pharmacies, expected by beginning of August this year. “We are confident the partnership between ex-NattoPharma and Biolab will be very fruitful as we foresee the product will benefit thousands of Brazilians across the country.”
Active Lifestylers
The bone and joint market is still expected to be driven by aging populations, but trends like Healthy Aging and Fitter for Longer open the market for younger demographics. Since 2000, views have drastically evolved about the importance of staying active and the role bone/joint health plays in one’s ability to do so.
Bone fractures are an obvious hindrance to staying active. In fact, every 3rd woman and every 5th man over the age of 50 will experience osteoporotic fractures. It is also worth noting that young female athletes have higher fracture risks than male counterparts.
Knowing the intricate balance between Vitamins D3 and K2, and its combined benefits for bone and heart health, a product that aims to support active lifestylers should incorporate both.
Major market penetration kicks off with leading brands Ex-NattoPharma ASA, world leader in vitamin K2 research and development, in collaboratoin with Complementary Medicines Group (CMG) Australia, announces successful penetration into the Australian and New Zealand markets, including supplying major Sponsor brands. This collaboration has resulted in exciting developments. First, Blackmores, Australia’s leading natural … Continue reading MenaQ7® K2 Launched in Australia/New Zealand
Major market penetration kicks off with leading brands
Ex-NattoPharma ASA, world leader in vitamin K2 research and development, in collaboratoin with Complementary Medicines Group (CMG) Australia, announces successful penetration into the Australian and New Zealand markets, including supplying major Sponsor brands.
This collaboration has resulted in exciting developments. First, Blackmores, Australia’s leading natural health brand, will utilize ex-NattoPharma’s MenaQ7® Vitamin K2 in a soon-to-be-released product that will be sold both online and through brick-and-mortar stores across Australia. BioCeuticals, supplier of high-quality practitioner-specific nutritional and therapeutic supplements, has also signed on to use its MenaQ7® Vitamin K2 in an upcoming product.
Another product concept released
In addition, another new product concept has already been released: Essential Nutrition Vitamin K2, a standalone bone health product featuring ex-NattoPharma’s MenaQ7® Vitamin K2 as MK-7, the only clinically validated and patented vitamin K2 as MK-7. The product is currently being sold online at www.essentialnutrition.net.au, and it will in November 2014 be sold exclusively through Go Vita, a 150-store retail natural products chain.
“Bone health is a serious concern, and the introduction of MenaQ7 Vitamin K2 to the Australian and New Zealand markets has been significant. We are energized,” says Craig Fallshaw, CMG Founder. “It is so validating to bring the only clinically validated, patented vitamin K2 as MK-7 to these markets.” In close collaboration with ex-NattoPharma ASA, CMG has leveraged relationships to bring the current product offering to market, as well as other opportunities for future products, and increase awareness of this important bone health ingredient. Most recently, CMG was a sponsor of the Complementary Medicines Australia (CMA) National Conference and 15th Annual Awards Dinner on October 30, 2014, where it was named the 2014 Wholesaler/Distributor of the Year.
“We are very pleased to make significant progress in Australia and New Zealand introducing our proprietary, patented, and clinically proven MenaQ7® Vitamin K2 as MK-7,” says Hogne Vik, CEO of ex-NattoPharma ASA. “We look forward to a long and successful relationship with CMG and its partner groups.”
About CMG
Complementary Medicines Group (CMG) is a service provider to the complementary medicine, food and over-the-counter pharmaceuticals industries. Offering raw materials, contract manufacturing, and marketing services, CMG was named the Complementary Medicines Australia 2011 Manufacturer, Wholesaler, or Distributor of the Year, and the 2014 Wholesaler/Distributor of the Year. For more information, visit cmgrouponline.com/au
As a complement to its award-winning Beginner’s DHA for Kids featuring MenaQ7® Vitamin K2, Wiley’s Finest Fish Oil introduced its Adult formula at Expo West 2017. And the company’s catchy campaign – “Climb the Peak of Health” – has been a huge success, landing on Times Square (NY, NY). “Playing off the fact that … Continue reading “Climb to the Peak of Health” Message in Times Square
As a complement to its award-winning Beginner’s DHA for Kids featuring MenaQ7® Vitamin K2, Wiley’s Finest Fish Oil introduced its Adult formula at Expo West 2017. And the company’s catchy campaign – “Climb the Peak of Health” – has been a huge success, landing on Times Square (NY, NY).
“Playing off the fact that Vitamin K2 is both a key nutrient in this formula and the name of the second highest mountain on earth, we decided to launch this product with the campaign theme of ‘Climb the Peak of Health’. We felt it would be a fun and inspirational way to engage our valued customers and encourage them to rise to the heights of good health,” explains Wiley’s Finest™ CEO Sam Wiley.
The new product combines both 500mg of concentrated EPA and DHA Omega-3 from Alaska Pollock Fish Oil with a meaningful dosage of MenaQ7® K2 per serving (80mcg). Wiley’s opted for this dose after reviewing studies that showed MenaQ7® K2 delivered positive health benefits at just 45mcg per day.
To learn more about the product, click here.
The importance of Vitamin K2 reached a new level of consumer awareness when it was mentioned specifically by Dr. Dennis Goodman, cardiologist and director of integrative medicine at New York University Langone Medical Center, as an important nutrient for heart health in an article that appeared in the April 25, 2016 issue of First For … Continue reading MenaQ7® Vitamin K2 Makes First For Women
The importance of Vitamin K2 reached a new level of consumer awareness when it was mentioned specifically by Dr. Dennis Goodman, cardiologist and director of integrative medicine at New York University Langone Medical Center, as an important nutrient for heart health in an article that appeared in the April 25, 2016 issue of First For Women.
Dr. Goodman, author of Vitamin K2: The Missing Nutrient for Heart and Bone Health, was interviewed with an esteemed panel of experts about how the appropriate form of a vitamin or supplement makes all the difference.
“Vitamin K2 activates substances that keep calcium in bone, where it should be,” he says, adding K1 doesn’t deliver this benefit. And if you’re also taking a calcium pill, it’s critical to take K2, he stresses. Otherwise, that calcium can build up in blood vessels to raise heart attack and stroke risk.
Dr. Goodman suggested First For Women readers take 45 mcg of K2 daily, “like Doctor’s Best Natural Vitamin K2 MenaQ7.”
To learn more, click here.